The Bridging study of RNTA06, which is indicated for the treatment of chronic angina, is completed and unblended,
2019.6.26
The Bridging study of RNTA06, which is indicated for the treatment of chronic angina, is completed and unblended,
TSH Biopharm Co., Ltd. (8432) announced today (6/26) that the Bridging study of RNTA06, which is indicated for the treatment of chronic angina, is completed and unblended, and the result meets the primary endpoint… View more
